Saroglitazar
Saroglitazar (INN, trade name Lipaglyn) is a drug for the treatment of type 2 diabetes mellitus and dyslipidemia. It is approved for use in India by the Drug Controller General of India.[1] Saroglitazar is indicated for the treatment of diabetic dyslipidemia and hypertriglyceridemia with type 2 diabetes mellitus not controlled by statin therapy. In clinical studies, saroglitazar has demonstrated reduction of triglycerides (TG), LDL cholesterol, VLDL cholesterol, non-HDL cholesterol and an increase in HDL cholesterol a characteristic hallmark of atherogenic diabetic dyslipidemia (ADD). It has also shown anti-diabetic medication properties by reducing the fasting plasma glucose and HBA1c in diabetes patients.
 | |
| Clinical data | |
|---|---|
| Trade names | Lipaglyn |
| Pregnancy category |
|
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C25H29NO4S |
| Molar mass | 439.57 g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
Mechanism of action
Saroglitazar is an insulin sensitizer. It is a first in class drug which acts as a dual PPAR agonist at the subtypes α (alpha) and γ (gamma) of the peroxisome proliferator-activated receptor (PPAR). Agonist action on PPARα lowers high blood triglycerides, and agonist action on PPARγ improves insulin resistance and consequently lowers blood sugar.[2]
Efficacy
Being a dual PPAR agonist, saroglitazar helps in controlling blood glucose and lipid parameters, especially high triglycerides and high non-HDL cholesterol.[3][4][5] A study done in rats concluded that saroglitazar has the potential to prevent the progression of retinopathy in diabetes patients.[6] Using preclinical models, it has also been shown to be useful in diabetic nephropathy.[7]
Safety
No major serious adverse events have been reported; however, long-term cardiovascular safety has not been established.[8]
References
- "Zydus Group launches new diabetic drug". The Times of India. Jun 6, 2013.
- "Lipaglyn (Saroglitazar) for Treating Hypertriglycerdemia in Type II Diabetes, India". Drug Development and Technology.
- Manoria PC, Chopra HK, Parashar SK, Dutta AL, Pinto B, Mullasari A, Prajapati S (December 2013). "The nuances of atherogenic dyslipidemia in diabetes: focus on triglycerides and current management strategies". Indian Heart Journal. 65 (6): 683–90. doi:10.1016/j.ihj.2013.10.015. PMC 3905264. PMID 24407538.
- Chatterjee S, Majumder A, Ray S (January 2015). "Observational study of effects of Saroglitazar on glycaemic and lipid parameters on Indian patients with type 2 diabetes". Scientific Reports. 5: 7706. Bibcode:2015NatSR...5E7706C. doi:10.1038/srep07706. PMC 4287720. PMID 25573251.
- Ramakrishnan S (2015). "From 'Make in India' to 'Made in India': the saroglitazar story". Indian Heart Journal. 67 (1): 8–10. doi:10.1016/j.ihj.2015.02.014. PMC 4382552. PMID 25820041.
- Joharapurkar A, Patel V, Kshirsagar S, Patel M, Savsani H, and Jain M (March 2021). "Effect of dual PPAR-α/γ agonist saroglitazar on diabetic retinopathy and oxygen-induced retinopathy". European Journal of Pharmacology. 899: 174032. doi:10.1016/j.ejphar.2021.174032. PMID 33753107.
- Jain, Mukul; Joharapurkar, Amit; Kshirsagar, Samadhan. "WO2017089979-Dual PPAR modulators for the treatment of diabetic nephropathy and related diseases". WIPO IP portal. WIPO. Retrieved 2 April 2021.
- Munigoti SP, Harinarayan CV (May 2014). "Role of Glitazars in atherogenic dyslipidemia and diabetes: Two birds with one stone?". Indian Journal of Endocrinology and Metabolism. 18 (3): 283–7. doi:10.4103/2230-8210.131134. PMC 4056123. PMID 24944919.